Abstract: Glucuronidation of SN-38 serves as an important metabolic pathway in determining the toxic effects of irinotecan. The role of UDP-glucuronosyltransferases (UGT) 1A9 in SN-38 glucuronidation pathway is very confusing. This study re-investigates the pathway through testing effects of bovine serum albumin (BSA) and the selective inhibitor on SN-38 glucuronidation in pooled human liver microsomes (HLM) and recombinant UGT1A1/UGT1A9. For UGT1A1, SN-38 glucuronidation was little affected by BSA. Whether in the presence of BSA or not, the reactions both obey Michaelis-Menten kinetics with closed Vmax/ Km values. For UGT1A9 and HLM, BSA can significantly accelerate SN-38 glucuronidation activities and similar effects are further observed on kinetic patterns. In the absence of BSA, reactions by HLM and UGT1A9 both display substrate inhibition kinetics. When BSA is included in the incubations, the reactions exhibit Michaelis-Menten kinetics. To get the true contribution of UGT1A9 in SN-38 glucuronidation, a relative activity factor (RAF) approach was additionally used. It is suggested that UGT1A9 and 1A1 contribute equally to SN-38 glucuronidation in HLM. Furthermore, in the presence of BSA, magnolol, a selective UGT1A9 inhibitor, displays moderate inhibition against HLM. Results together conclude that UGT1A9 serves as an additional important contributor to hepatic SN-38 glucuronidation.
SN-38 is an active form of irinotecan that is widely used in the treatment of colorectal and lung cancers. It is observed that irinotecan medication is sometimes associated with life-threatening gastrointestinal toxicities. It has been established that glucuronidation of SN-38 acts as a major determinant factor protecting patients against irinotecan-related toxicities.
Nearly all UGT1A enzymes except UGT1A4 are involved in SN-38 glucuronidation [1] [2] [3] . Of those UGTs, it is generally regarded that SN-38 glucuronidation in humans is mainly catalysed by UGT1A1 [4] . The factors decreasing activity of UGT1A1, such as polymorphisms and co-administered chemical inhibitors, can make the related toxicities even worse in patients receiving irinotecan medication [5] [6] [7] .
However, several different studies indicate that UGT1A1 may be not the sole important isoform in SN-38 glucuronidation. One previous in vitro study displayed that the reaction correlated well with UGT1A9 activity in HLM [8] . Clinical studies also demonstrated that UGT1A9 polymorphism acted as an additional indicator for irinotecan toxicities [9, 10] . Due to the possible genetic linkage to UGT1A1, the role of UGT1A9 in SN-38 glucuronidation pathway has been still neglected.
In fact, the conclusion that UGT1A1 played a dominant role in SN-38 glucuronidation was drawn mainly from in vitro studies. It was indicated that recombinant UGT1A1 exhibited much higher activity than other isoforms [1] . However, the activity of the recombinant isoform sometimes cannot reflect true contribution of the isoform in the overall metabolic pathway. The instance was previously exemplified in that UGT1A10 played an important role in human intestinal glucuronidation of magnolol [11] . Furthermore, previous studies indicated that the typical in vitro incubation system was prone to decrease the activity of UGT1A9 due to the presence of fatty acids released from the microsomal membrane [12, 13] . Therefore, the contribution of UGT1A9 might have been underestimated previously in SN-38 glucuronidation.
The evidence together encourages us to investigate the role of UGT1A9 in SN-38 glucuronidation via testing effects of bovine serum albumin (BSA) on pooled HLM and recombinant UGT1A1/1A9, as well as conducting selective inhibition studies and relative activity factor (RAF) approach. It is hoped that this study can help understand the key factors determining irinotecan-related toxicities.
Materials and Methods
Chemicals and enzyme sources. SN-38 (98%), oestradiol (98%), 4-methylumbelliferyl b-D-glucuronide (4MuG, >98%) and magnolol (98%) were purchased from J&K Scientific Ltd (Shanghai, China). Bovine serum albumin (BSA, 96%), propofol (98%) and UDPGA (>98%) were purchased from Sigma-Aldrich LLC (Shanghai, China). Pooled HLM (n = 25, Lot. X008064) were purchased from RILD Co. Ltd (Shanghai, China). Recombinant UGT1A1 and UGT1A9 were purchased from BD Co. Ltd (Shanghai, China). SN-38 glucuronidation assays. Glucuronidation assays were conducted in a reaction mixture of 200 lL containing 50 mM TrisHCl buffer (pH 7.4), 5 mM MgCl 2 , 4 mM UDPGA. For HLM, alamethicin (5% microsomal protein concentrations) was used to activate the microsomes in an ice bath for 20 min. For recombinant UGT1A1 and UGT1A9, no activation is required. SN-38 was dissolved in methanol and the final concentration of methanol in the reaction mixture did not exceed 1% (v/v). After pre-incubation at 37°C for 3 min., the reactions were started by the addition of UDPGA. The reactions were terminated by the addition of cold methanol containing 100 nM 4MuG (200 lL). The mixture was kept on ice for 30 min. and then centrifuged at 20,000 9 g for 20 min. at 4°C to remove protein. Aliquots of supernatants were stored at À20°C until analysis on LC-MS/MS.
Effects of BSA on glucuronidation. Preliminary experiments indicated that SN-38 glucuronidation occurred in the linear range of at least 0-120 min. Various concentrations of SN-38 (0-100 lM) were incubated with 0.01 mg/mL HLM, UGT1A1 or UGT1A9 in the reaction mixture (200 lL) in the presence or absence of 0.1% BSA. The incubations were conducted at 37°C for 30 min. in triplicate determinations. The reaction was stopped by adding 200 lL cold methanol (containing 100 nM 4MuG). After centrifugation to remove protein, 5 lL supernatants were analysed on LC-MS/MS. To obtain the kinetic parameters, kinetic data were fitted into Michaelis-Menten model (equation 1) or substrate inhibition model (equation 2).
where v is the rate of the reaction, [S] is the substrate concentration, V max is the maximum velocity estimate, and K m is the Michaelis-Menten constant.
where K s describes affinity of SN-38 binding to reaction site, and K si is the substrate inhibition constant.
RAF approach application. To achieve an accurate understanding of roles of UGT1A1 and UGT1A9 in hepatic SN-38 glucuronidation, glucuronidation activity in recombinant systems was scaled to HLM through the RAF approach [11] . Glucuronidation of oestradiol-3-OH and propofol was used as probe reactions for activity of the human liver UGT1A1 and 1A9, respectively [14] . To calculate RAF values (dividing the probe reaction rate in HLM by that in the recombinant enzyme), oestradiol (100 lM) and propofol (200 lM) were employed in glucuronidation assays with 0.1 mg/mL HLM and UGT1A1/ UGT1A9 in the presence of 0.1% BSA, respectively. To estimate the SN-38 (2 lM) glucuronidation rate of UGT1A1 and UGT1A9 in HLM (V i ), the reaction rate in the recombinant enzyme was multiplied by the corresponding RAF value. The relative contribution of UGT1A1/ UGT1A9 is calculated by dividing the V i by SN-38 glucuronidation rate in HLM (V total ) (equation 3).
Inhibition assays. SN-38 (2 lM) and various concentrations of magnolol (0-5 lM) were co-incubated with HLM, UGT1A1, UGT1A9 in the presence of 0.1% BSA. Detailed incubation information was described as above. All incubations were performed in triplicate determinations.
Analytical methods. SN-38 glucuronidation samples were analysed using AB Sciex Eksigent ekspert TM UltraLC100 system coupled to an AB Sciex 4000 QTRAP MS (AB, Foster City, San Francisco, California, USA) equipped with an electrospray ionization interface (ESI). Chromatographic separation was achieved on a Phenomenex column (4.6 mm i.d. 950 mm, 3 lm). The column temperature was kept at 40°C. The mobile phase was composed of methanol (A) and aqueous ammonium acetate (B) (5 mM) at a flow rate of 0.4 mL/min., with a gradient: 0-2 min., 40% B -15% B; 2-4 min., 15% B-5% B; 4-4.5 min., 5% B-40% B; 4.5-8 min., balance to 40% B. The injection volume was 5 lL. 4-MuG, SN-38 and its glucuronide were eluted at 1.81, 2.74 and 2.10 min., respectively ( fig. 1) . The mass spectrometric conditions were optimized as follows: ESI source block temperature at 150°C, desolvation temperature at 550°C, capillary voltage 3200 V, desolvation flow at 700 L/h cone gas (nitrogen) flow at 150 L/h and cone voltage at 30 V. Data were acquired in multiple reaction monitoring (MRM) mode. The optimized mass transition ion pairs (m/z) were 390.8/347 for SN-38, 566.8/347 for SN-38 glucuronide and 351.0/175.0 for 4-MuG. Oestradiol and propofol glucuronidation samples were analysed as previously reported [11] .
Results

Effects of BSA on SN-38 glucuronidation in HLM.
The presence of 0.1% BSA exhausted significantly accelerated effects against SN-38 glucuronidation in HLM ( fig. 2 ). In the absence of BSA, SN-38 glucuronidation was well described by substrate inhibition kinetics, with V max , K s and K si values of 21 pmol/min/mg, 3.3 and 113 lM, respectively. When BSA was included in the incubations, the reaction kinetics changed into Michaelis-Menten kinetics, with V max and K m values of 36 pmol/min/mg and 1.2 lM, respectively.
Effects of BSA on SN-38 glucuronidation in UGTs.
As shown in fig. 3A , UGT1A1 catalysed SN-38 glucuronidation was little affected by BSA. Whether in the presence of BSA or not, the reactions both displayed Michaelis-Menten kinetics, with much closed V max and K m values (table 1) . Contrary to UGT1A1, UGT1A9-mediated SN-38 glucuronidation was significantly facilitated by BSA ( fig. 3B ). In kinetic assays without BSA, the reaction showed substrate inhibition kinetics. The V max , K s and K si values were demonstrated to be 12 pmol/min/mg, 1.3 lM and 127 lM, respectively. When BSA was included in the incubation, the reaction kinetics followed the Michaelis-Menten model, with V max and K m values of 17 pmol/min/mg and 0.62 lM, respectively.
RAF studies.
As the recombinant UGT1A1 showed much higher activity than UGT1A9, we further conducted RAF approach to decipher the true roles of these two UGTs in SN-38 glucuronidation in HLM. The rate of oestradiol-3-O-glucuronidation in recombinant UGT1A1 was much higher than that in HLM, and the RAF value for UGT1A1 was calculated to be 0.10. Propofol glucuronidation occurred at a slightly higher rate in recombinant UGT1A9 than that in HLM, and the RAF value for UGT1A9 was 0.62. After determination of SN-38 glucuronidation rates (2 lM) by HLM, UGT1A1 and UGT1A9, the respective RAF values for these two UGTs indicated that UGT1A9 contributed 41% to the activity in HLM, while UGT1A1 contributed 47% (fig. 4) .
Inhibition assays.
Magnolol has been characterized as a selective inhibitor of UGT1A9 [15] . It was employed here to validate the role of UGT1A9 in SN-38 glucuronidation in HLM. As shown in fig. 5 , magnolol (5 lM) can potently decrease the activity of UGT1A9 in catalysing SN-38 glucuronidation, with remaining activity below 5% of the control. In contrast, magnolol displayed very few effects against UGT1A1 ( fig. 5 ). Different from UGT1A1 and 1A9, magnolol showed moderate inhibition towards HLM-mediated SN-38 glucuronidation, with remaining activity of 54% of the control.
Discussion
This in vitro study re-investigated the roles of UGT1A1 and UGT1A9 in hepatic glucuronidation of SN-38. BSA effects indicate that BSA can not only accelerate activities of UGT1A9 and HLM but also exert similar effects towards the kinetic patterns for UGT1A9 and HLM. The RAF approach additionally indicates that recombinant UGT1A1 is highly capable of catalysing SN-38 glucuronidation, which may overshadow the contribution of UGT1A9. Results together indicate that UGT1A9 acts as an additional important contributor, and the conclusion is further confirmed by selective inhibition studies.
In this study, BSA is demonstrated to display different modulating effects towards HLM and UGTs. BSA showed very little effects against UGT1A1, which is not consistent with one previous study by using 4-methylumbelliferone as the substrate [12] . The disagreement may result from that UGT1A1 showed much higher affinity to SN-38 than to 4-methylumbelliferone. As a result, fatty acids in the reaction mixture decrease activity of this isoform in catalysing 4-methylumbelliferone glucuronidation rather than SN-38 glucuronidation. Of interest is the observation that the presence of BSA results in similar changes in the kinetic pattern for SN-38 glucuronidation by UGT1A9 and HLM (figs 2 and 3B). It is strongly suggested that the role of UGT1A9 in hepatic SN-38 glucuronidation cannot be ignored. In addition, BSA appears to have the more effective accelerating effects in the activity of human liver microsomal UGT1A9 than the recombinant isoform (table 1) . This is consistent with the studies by using the specific UGT1A9 substrates, entacapone and propofol [12, 13] .
This study demonstrates that UGT1A1 and UGT1A9, rather than one single isoform, both contribute significantly to SN-38 glucuronidation. When the factors decrease, activities of both these two UGTs occur, and patients will be at very high risk of irinotecan-related toxicities. Inherited UGT polymorphisms have drawn extensive attention in irinotecan medication. It was reported that several polymorphisms for UGT1A1 and UGT1A9 (e.g. UGT1A1*6/*28, UGT1A9*3) could result in reduced catalytic activities [8, 16] . When patients carry the genotypes conferring low activities of both UGT1A1 and UGT1A9, irinotecan medication should be given with caution and a lower dosage may be better to prevent severe side Y: Kinetic data were gained from the incubations that contained 0.1% BSA. N: Kinetic data were gained from the incubations that contained no BSA. effects. It is noteworthy that UGT1A1 and UGT1A9 share several common chemical inhibitors. Several reported clinical drugs and herb constituents, such as diethylstilbestrol, canagliflozin, licochalcone A, scutellarin and hesperetin, can potently inhibit activities of both UGT1A1 and UGT1A9 [17] [18] [19] [20] . When irinotecan is co-administered with those drugs, the related severe toxicities might be more serious. In summary, different from the previous studies, this study proves that hepatic glucuronidation of SN-38 is mainly catalysed by UGT1A9 and UGT1A1. In order to reduce related toxic effects, it should be better to take into consideration of factors decreasing activities of UGT1A9 along with UGT1A1 in irinotecan medication.
